⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ABL News
Abacus Global Management, Inc. Class A Common Stock
Multispecific Antibodies Market Report 2026: Forecast to Reach $60 Billion by 2031, Driven by Expanding Clinical Pipeline and Proprietary Technologies
globenewswire.com
AMGN
JNJ
PFE
REGN
MRK
ABBV
BMY
GILD
AZN
XNCR
GEN
ABL
Dominica to Build World's Tallest Parrot Statue
accessnewswire.com
ABL
CD137 Targeted Therapy Research Report 2026-2030: Market Opportunities, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insights - ResearchAndMarkets.com
businesswire.com
GMAB
ABL
BNTX
BCRX
CD137 Targeted Therapy Research Report 2026-2030: 90 Therapies in Clinical Trials, Upcoming Commercial Launches, Global & Regional Clinical & Commercial Trends,
globenewswire.com
GILD
BMY
REGN
MRK
PFE
ABBV
BIIB
AZN
AMGN
NVS
GMAB
ABL
BNTX
ABX Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm
prnewswire.com
ABX
ABL
ABX Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm
globenewswire.com
ABX
ABL
Ascend Advanced Therapies – ABL Inc. verstärkt sein Führungsteam weiter, um seine ambitionierte Wachstumsstrategie voranzutreiben
accessnewswire.com
ABL
ABL Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm
globenewswire.com
ABL
ABX
ABL Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm
businesswire.com
ABL
Abacus Global Management Announces Transfer of Listing of its [Class A] Common Stock to the New York Stock Exchange with New Ticker Symbol “ABX”
globenewswire.com
ABL